Want to see EBS full AI Analyst Report?
EarningsQ2 2026 Earnings Report
EBS Q2 2026 EPS Results
Actual EPS$0.60
Consensus EPS-$0.09
Beat/MissBeat by +$0.68
One Year Ago EPS$0.16
EBS Q2 2026 Revenue Results
Actual Revenue$234.30M
Expected Revenue$177.50M
Beat/MissBeat by +$56.80M
YoY Revenue Growth+66.29%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeAfter Close
Conference CallWednesday, August 5, 2026
EBS Upcoming Earnings
Emergent Biosolutions's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
EBS Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call reflected a balance of strong near-term operational execution and financial results—Q2 revenue and adjusted EBITDA materially exceeded expectations, driven by accelerated MCM deliveries and improved margins—alongside significant commercial headwinds in the naloxone business that prompted a $191M noncash impairment and a downward revision to full-year revenue and profitability guidance. Management is taking proactive restructuring and capital allocation actions (debt refinancing, share repurchases, $40M annualized cost-savings plan) to preserve liquidity and position the company for 2027, but the naloxone competitive dynamics and guidance cuts temper the otherwise strong quarter.Company Guidance
Q2 Revenue Beat
Second-quarter revenue of $234 million, materially above the prior guidance high end of $185 million; year-to-date revenue $390 million, up from $363 million year-over-year (+7.4%).
Strong Adjusted EBITDA and Margin Expansion
Q2 adjusted EBITDA of $97 million with a 41% margin versus $33 million and a 23% margin in Q2 2025 (adjusted EBITDA up ~194% YoY; margin up 18 percentage points). Year-to-date adjusted EBITDA $132 million (34% margin) versus $112 million (30% margin) prior year (+17.9% YoY).
Improved Gross Margins Driven by Product Mix
Q2 adjusted gross margin 58% versus 49% in Q2 2025 (+9 percentage points); year-to-date adjusted gross margin 56%, up ~100 basis points YoY.
Medical Countermeasures Momentum and Contract Wins
MCM revenue of $168 million in Q2—highest Q2 since 2020—driven by accelerated U.S. government deliveries; contract modifications included $52.7 million for ACAM2000 and $64.5 million for botulism antitoxin, and the company secured over 10 contract awards year-to-date. International MCM sales represent ~20% of first-half MCM revenues.
Cash, Liquidity & Balance Sheet Actions
Ended Q2 with $140 million cash and $190 million total liquidity; collected ~$145 million of accounts receivable in July which materially improved early-Q3 cash. Gross debt improved to $590 million (from $700 million prior year); net debt $450 million with a stable net leverage ratio of 1.9x LTM adjusted EBITDA. Completed term loan refinancing (new $150M term loan, extended maturity to 2031, lower rates) and authorized a $75 million senior note repurchase program plus a $50 million share repurchase program.
Capital Allocation and Share Repurchases
Repurchased 1.1 million shares for ~$9 million in Q2 and 1.9 million shares for $18 million year-to-date; $37.5 million remains available under the authorized share repurchase program.
Restructuring to Improve Cost Structure
Announced restructuring actions expected to deliver approximately $40 million of annualized savings, including ~90 headcount reductions, closure of 2 wet labs, sale of an underutilized office building (~$6.4M sale), and exit of a central warehouse lease; cost to achieve estimated at ~$11 million.
EBS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed